Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial

The Lancet

Volumn 380, Issue 9839, 2012, Pages 358-365

  Hauschild, Axel ^a   Grob, Jean Jacques ^b   Demidov, Lev V ^c   Jouary, Thomas ^d   Gutzmer, Ralf ^e   Millward, Michael ^f   Rutkowski, Piotr ^g   Blank, Christian U ^h   Miller Jr , Wilson H ⁱ   Kaempgen, Eckhart ^j   Martín Algarra, Salvador ^k   Karaszewska, Boguslawa ^l   Mauch, Cornelia ^m   Chiarion Sileni, Vanna ⁿ   Martin, Anne Marie ^o   Swann, Suzanne ^o   Haney, Patricia ^o   Mirakhur, Beloo ^o   Guckert, Mary E ^o   Goodman, Vicki ^o   Chapman, Paul B ^p   more..

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b AIX MARSEILLE UNIVERSITY   (France)

^c N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

^d HÔPITAL SAINT ANDRÉ   (France)

^e HANNOVER MEDICAL SCHOOL   (Germany)

^f UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^g INSTITUTE OF ONCOLOGY   (Poland)

^h ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

ⁱ MCGILL UNIVERSITY   (Canada)

^j UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^k UNIVERSITY CLINIC OF NAVARRA   (Spain)

^l Przychodnia Lekarska KOMED   (Poland)

^m UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

ⁿ VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^o GLAXOSMITHKLINE   (United States)

^p MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; DABRAFENIB; DACARBAZINE;

ADULT; AGED; ARTHRALGIA; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; FATIGUE; FEMALE; FEVER; GENE MUTATION; HUMAN; HYPERKERATOSIS; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MELANOMA; NAUSEA; NEUTROPENIA; OPEN STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

EID: 84864285704     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(12)60868-X     Document Type: Article

References (15)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C,Parkin DM. GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10. Lyon, France: International Agency for Research on Cancer; 2010.
3. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-54. (Pubitemid 34716871)
4. Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005; 353: 2135-47. (Pubitemid 41653105)
5. Jakob JA, Bassett RL Jr, Ng CS, et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 2011; published online Dec 16. DOI:10.1002/cncr.26724.
6. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-16.
7. GlaxoSmithKline. BRF113683 Clinical Study Report. Data on File, May 2012.
8. Trefzer U, Minor D, Ribas A, et al. BREAK-2: a Phase IIA trial of the selective BRAF kinase inhibitor GSK2118436 in patients with BRAF mutation-positive (V600E/K) metastatic melanoma. Pigment Cell Melanoma Res 2011; 24: 1020.
9. Eisenhauer EA, Therasse P, Bogarets J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-47.
10. Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012; 366: 707-14.
11. Falchook GS, Long GV, Kurzrock R, et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumors: a phase 1 dose-escalation trial. Lancet 2012; 379: 1893-901.
12. Nazarian R, Shi H, Wang Q, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010; 468: 973-77.
13. Poulikakos PI, Persaud Y, Janakiraman M, et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 2011; 480: 387-90.
14. Johannessen CM, Boehm JS, Kim SY, et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 2010; 468: 968-72.
15. Straussman R, Morikawa T, Shee K, et al. Tumor microenvironment contributes to innate RAF-inhibitor resistance through HGF secretion. Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; Chicago, Illinois; March 31-April 4, 2012. 4837.